Developed to counter the then-new United States fighters such as the McDonnell Douglas F-15 Eagle and the General Dynamics F-16 Fighting Falcon, the Mikoyan MiG-29 (NATO reporting name "Fulcrum") ...

The MiG-29 was designed as a supersonic air superiority fighter. Introduced between 1959 and 1977, the MiG-21, MiG-23, MiG-25, MiG-27, and MiG-29 all have fascinating stories to tell and served as the ...

FSHD, or facioscapulohumeral muscular dystrophy, is a neuromuscular disorder characterized by muscle weakness in the face, shoulders and arms. It’s primarily caused ...

He’s accomplished a lot in his 29 years - three Super Bowl victories, six Pro Bowls, one Offensive Player of the Year sward, two MVP awards, three Super Bowl MVP awards, and a loving family with ...

A report by the Military Watch Magazine said that the two Su-27 Fighters were destroyed by Russian aviation assets, while ground-based air defences shot down the MiG-29. Disclaimer: A number of claims ...

Polish Foreign Minister Radosław Sikorski revealed during a visit to Kyiv on Friday that Poland is considering transferring MiG-29 fighter jets to Ukraine to help it defend itself against ...

If allies agree on a plan to help patrol Poland’s airspace, Warsaw would be willing to transfer its remaining fleet of Soviet-era MiG-29 fighter jets to Ukraine, Polish Foreign Minister Radoslaw ...

Fulcrum BioEnergy, Inc., a California-based company, has filed for Chapter 11 bankruptcy protection in a Delaware court. Backed by companies including WM and Marathon Petroleum, the organisation had ...

Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and ...

Fulcrum Therapeutics (NASDAQ:FULC) announced Thursday after its lead program for protein kinase inhibitor losmapimod, in-licensed from GSK (GSK), failed to reach main goals in patients with a rare ...

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure. The licensing deal with the Big Pharma was agreed ...

Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock is trading lower on Thursday after the company released data from the Phase 3 REACH trial evaluating losmapimod in patients with Facioscapulohumeral ...